Association of differential gene expression with imatinib mesylate and omacetaxine mepesuccinate toxicity in lymphoblastoid cell lines

<p>Abstract</p> <p>Background</p> <p>Imatinib mesylate is currently the drug of choice to treat chronic myeloid leukemia. However, patient resistance and cytotoxicity make secondary lines of treatment, such as omacetaxine mepesuccinate, a necessity. Given that drug cyto...

Full description

Bibliographic Details
Main Authors: Kulkarni Hemant, Göring Harald H H, Diego Vincent, Cole Shelley, Walder Ken R, Collier Greg R, Blangero John, Carless Melanie A
Format: Article
Language:English
Published: BMC 2012-08-01
Series:BMC Medical Genomics
Subjects:
Online Access:http://www.biomedcentral.com/1755-8794/5/37

Similar Items